Galmed Pharmaceuticals Ltd. (GLMD) intrinsic value & 10-year financials
Galmed Pharmaceuticals Ltd. (GLMD) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Revenue (FY2025)
- —
- Revenue growth (10-yr CAGR)
- 108.9%
- ROIC (10-yr avg)
- -90.8%
- Free cash flow (FY2025)
- —
GLMD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.3M | $2.39 | — | — | -64.2% |
| FY2024 | — | -$7.5M | $8.08 | — | — | -49.8% |
| FY2023 | — | -$6.9M | $2.50 | — | — | -60.4% |
| FY2022 | — | -$17.9M | $10.65 | -$18.5M | — | -90.9% |
| FY2021 | — | -$32.5M | $19.80 | -$32.9M | — | -99.5% |
| FY2020 | $0 | -$28.8M | — | -$26.3M | — | -65.9% |
| FY2019 | $0 | -$20.5M | — | -$14.9M | — | -37.9% |
| FY2018 | $2.0M | -$9.9M | — | -$9.1M | -525.8% | -32.2% |
| FY2017 | $1.1M | -$12.3M | — | -$12.1M | -1139.5% | -214.1% |
| FY2016 | $467.0K | -$17.0M | — | -$12.1M | — | -193.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Galmed Pharmaceuticals Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Galmed Pharmaceuticals Ltd. has historically struggled to out-earn its cost of capital, averaging just -50.5% ROIC.
Galmed Pharmaceuticals Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Galmed Pharmaceuticals Ltd. is modeled at -11.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-31.38 per share.